Business
NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%
Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported fina
About this update from Neuroone Medical Technologies Corporation
[{"type":"image","alt":"NeuroOne Medical Technologies Corporation","displaySize":"","headline":null,"caption":"NeuroOne Medical Technologies Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/819fe13d4f4c15d1a815f2aae4dd578b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pp0tg2T4IB9hXCYxVLu0sA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/819fe13d4f4c15d1a815f2aae4dd578b","width":300,"height":48}},"lazy":false},{"type":"text","content":"Filed 510(k)Submission with FDA for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Ahead of Schedule","length":114,"tagName":"p"},{"type":"text","content":"Company Fully Funded Through at Least Fiscal Year 2026 Following Oversubscribed $8.2 Million Capital Raise","length":106,"tagName":"p"},{"type":"text","content":"EDEN PRAIRIE, Minn., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the second quarter of fiscal year 2025 ended March 31, 2025.","length":356,"tagName":"p"},{"type":"text","content":"Recent Company Highlights","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Successfully filed FDA submission ahead of schedule for the OneRF® Trigeminal Nerve Ablation System to treat facial pain, with a potential to generate revenues in late calendar year 2025 if cleared by the FDA.","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed an oversubscribed capital raise with institutional investors in April 2025 totaling $8.2 million in net proceeds. The Company is debt free and anticipates being fully funded through at least fiscal year 2026.","length":218,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company reaffirms its fiscal year 2025 guidance of product revenue, which excludes license revenue received of $3.0 million, to range between $8.0 to $10.0 million, representing an increase of between 132% and 190% when compared to product revenue of $3.5 million in fiscal year 2024.","length":288,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthening the Company’s m...